Xavier I. Rivera

Phase 2 Open‐Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle‐Cell and Indolent Lymphomas

D. Mahadevan, J. Schatz, J. Guillén-Rodríguez, 2018, Clinical lymphoma, myeloma & leukemia.

A Phase II Exploratory Study of PXD-101 (Belinostat) Followed by Zevalin in Patients with Relapsed Aggressive High-Risk Lymphoma

J. Schatz, M. Schmelz, J. Guillén-Rodríguez, 2017, Oncology.

Double hit lymphoma presenting as haemophagocytic lymphohistiocytosis

J. Schatz, S. Puvvada, L. Mcghan, 2017, BMJ Case Reports.

Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin Lymphoma: Final Results of a Phase II Study

D. Mahadevan, J. Schatz, J. Guillén-Rodríguez, 2018, Oncology.

Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib

S. James, S. Amrock, A. Kittai, 2018, Cancer.

The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model

D. Brander, T. Siddiqi, B. Hill, 2021, Clinical Cancer Research.

A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: Results from a multicenter retrospective cohort study.

B. Hill, D. Persky, A. Danilov, 2020, Leukemia research.

Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission.

J. Vose, M. Bast, F. Hernandez-Ilizaliturri, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.